[닫기]
잠시만 기다려 주세요. 로딩중입니다.

Higher thoracic radiation dose is beneficial in patients with extensive small cell lung cancer

Radiation Oncology Journal 2019년 37권 3호 p.185 ~ 192
 ( Yoon Han-Gyul ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Radiation Oncology

 ( Noh Jae-Myoung ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Radiation Oncology
 ( Ahn Yong-Chan ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Radiation Oncology
 ( Oh Dong-Ryul ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Radiation Oncology
 ( Pyo Hong-Ryull ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Radiation Oncology
 ( Kim Hae-Young ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Radiation Oncology

Abstract


Purpose: The effectiveness of thoracic radiation therapy (TRT) in extensive-stage small cell lung cancer (ES-SCLC) patients is increasingly reported, but there is no definite consensus on its application. The aim of this study was to identify factors associated with better outcomes of TRT among patients with ES-SCLC, focusing on whether a higher TRT dose could improve treatment outcome.

Materials and Methods: The medical records of 85 patients with ES-SCLC who received TRT between January 2008 and June 2017 were retrospectively reviewed. Eligibility criteria were a biological effective dose with α/β = 10 (BED) higher than 30 Gy10 and completion of planned radiotherapy.

Results: During a median follow-up of 5.3 months, 68 patients (80.0%) experienced disease progression. In univariate analysis, a BED >50 Gy10 was a significant prognostic factor for overall survival (OS; 40.8% vs. 12.5%, p = 0.006), progression-free survival (PFS; 15.9% vs. 9.6%, p = 0.004), and intrathoracic PFS (IT-PFS; 39.3% vs. 20.5%, p = 0.004) at 1 year. In multivariate analysis, a BED >50 Gy10 remained a significant prognostic factor for OS (hazard ratio [HR] = 0.502; 95% confidence interval [CI], 0.287?0.876; p = 0.015), PFS (HR = 0.453; 95% CI, 0.265?0.773; p = 0.004), and IT-PFS (HR = 0.331; 95% CI, 0.171?0.641; p = 0.001). Response to the last chemotherapy was also associated with better OS in both univariate and multivariate analysis.

Conclusion: A TRT dose of BED >50 Gy10 may be beneficial for patients with ES-SCLC. Further studies are needed to select patients who will most benefit from high-dose TRT.

키워드

Small cell lung carcinoma; Extensive-stage; Radiotherapy dosage
원문 및 링크아웃 정보
 
등재저널 정보